Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E31.53 EPS (ttm)1.00 Insider Own0.04% Shs Outstand6.07B Perf Week0.16%
Market Cap191.62B Forward P/E12.04 EPS next Y2.62 Insider Trans-1.32% Shs Float6.06B Perf Month6.74%
Income6.18B PEG5.00 EPS next Q0.50 Inst Own70.60% Short Float0.75% Perf Quarter-8.24%
Sales53.24B P/S3.60 EPS this Y-21.50% Inst Trans-1.54% Short Ratio1.86 Perf Half Y-7.66%
Book/sh10.43 P/B3.03 EPS next Y8.61% ROA3.60% Target Price37.76 Perf Year-0.05%
Cash/sh2.37 P/C13.33 EPS next 5Y6.31% ROE9.70% 52W Range27.49 - 36.72 Perf YTD1.56%
Dividend1.20 P/FCF107.59 EPS past 5Y1.60% ROI7.30% 52W High-14.04% Beta0.91
Dividend %3.80% Quick Ratio0.90 Sales past 5Y-5.60% Gross Margin76.60% 52W Low14.79% ATR0.67
Employees97900 Current Ratio1.10 Sales Q/Q7.90% Oper. Margin15.10% RSI (14)46.87 Volatility1.64% 2.03%
OptionableYes Debt/Eq0.70 EPS Q/Q-36.80% Profit Margin11.60% Rel Volume0.72 Prev Close31.59
ShortableYes LT Debt/Eq0.48 EarningsNov 01 BMO Payout116.50% Avg Volume24.53M Price31.56
Recom2.40 SMA20-0.50% SMA50-1.63% SMA200-3.71% Volume17,621,818 Change-0.09%
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Dec-06-16 04:19PM  The Latest Buzz in Biotech at Motley Fool
12:58PM  Sanofi May Battle Johnson & Johnson For European Biotech Actelion
10:12AM  Pfizer Leukemia Drug Meets Primary Endpoint in Phase III
10:00AM  Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire
07:05AM  Trump's corporate tax holiday could spur pharma M&A Reuters
06:00AM  What a Dividend Payout Ratio Can (and Can't) Tell You at Morningstar
01:30AM  Can't buy love? Drug price hikes put sex beyond reach
Dec-05-16 04:07PM  Sanofi to Explore Counterbid for Actelion Amid J&J Talks at Bloomberg
12:04PM  Allergan's Strength Lies In Its New Products And Robust Pipeline
10:33AM  Robust Pipeline Supports 5.5% Dividend Yield
09:48AM  2 Stocks That Could Soar Under a Donald Trump Presidency at Motley Fool
09:08AM  Pfizer (PFE) Presents Favorable Data on Leukemia Candidate
08:43AM  Pfizer's blood cancer drug Bosulif effective in untreated patients Reuters
08:00AM  Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia Business Wire
Dec-04-16 09:48AM  Does Pfizer Pass Warren Buffetts Test? at Motley Fool
Dec-03-16 01:04PM  Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions
01:00PM  New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Business Wire
11:00AM  Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting GlobeNewswire
12:03AM  [$$] New Tax Rules on Corporate Inversions Face Uncertain Future at The Wall Street Journal
Dec-02-16 04:41PM  Forget Pfizer: Here Are 3 Better Dividend Stocks at Motley Fool
03:35PM  $50 Billion Quant Fund Is Making New Bets On These Stocks at Insider Monkey
03:02PM  Regeneron's CEO Blasts Peers on Innovation at Motley Fool
02:42PM  The Numbers Behind a Pharma CEO Shouting Match at Bloomberg
01:08PM  Morgan Stanley: Chevron, Pfizer Will be Big Winners in 2017 at TheStreet
11:41AM  [$$] Tax Rules on Corporate Inversions Face Uncertain Future at The Wall Street Journal
11:23AM  How China Makes Money (BABA, PFE) at Investopedia
11:05AM  Mercks Gardasil and What It Could Mean
09:33AM  Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug
09:15AM  5 Best Dividend Stocks To Buy Right Now at Insider Monkey
08:04AM  The Word on the Street: What Analysts Are Estimating for Pfizer Now
07:15AM  Coverage initiated on Pfizer by Guggenheim
06:40AM  Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda
Dec-01-16 06:33PM  Pharma execs weigh in on possible changes under Trump Reuters
04:48PM  Here's the Best Dividend Stock in Big Pharma at Motley Fool
03:42PM  IBM, Pfizer Announce Partnership (IBM, PFE) at Investopedia
11:05AM  Recent R&D Developments from Merck You Wont Want to Miss
11:04AM  Inside Pfizers Recent Corporate and Pipeline Developments
10:04AM  Major Product Developments for Pfizer
10:04AM  How Much Could Gilead Sciencess Revenues Fall beyond 2016?
10:00AM  Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference Business Wire
09:27AM  Lyrica Showed Efficacy in Children With Epilesey (PFE) at Investopedia
09:21AM  Tiger Cub Lee Ainslies Top Stock Picks at Insider Monkey
09:08AM  Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study
08:50AM  Pfizer to use IBM Watson supercomputing to find new drugs at
08:04AM  Pfizers Profitability and Financial Guidance
08:00AM  Pfizer Partners With IBM Watson To Advance Cancer Drug Discovery at Forbes
08:00AM  LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint Business Wire
08:00AM  IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery PR Newswire
Nov-30-16 04:41PM  What's Pfizer's Excuse for Not Buying Exelixis? at Motley Fool
04:01PM  Omnicell's Performance Center Integrates with Hospira's Infusion Pump Software PR Newswire
12:06PM  Allergan's CEO Signals Confidence With $1 Million Purchase Of Stock at Forbes
11:04AM  These Pfizer Products Saw Falling Revenues in 3Q16
10:49AM  3 High-Yield Dividend Stocks to Buy in December at Motley Fool
10:27AM  10 Undervalued High-Yield Dividend Stocks Worth Buying Today
10:22AM  Pfizer reports positive REFLECTIONS data (PFE) at Investopedia
10:04AM  Understanding Pfizers Growth Contributors
08:58AM  Pfizer's Herceptin biosimilar succeeds in key breast cancer study
08:38AM  Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab
08:30AM  Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for PF-05280014, a Potential Biosimilar to Herceptin®1 (trastuzumab) Business Wire
08:04AM  Pfizers Innovative and Essential Health Businesses
06:17AM  [$$] Pfizer: Easy to Swallow With Low P/E, 3.8% Yield at
06:00AM  10 Cheap High-Quality Dividend Payers at Morningstar
Nov-29-16 05:24PM  In Case You Missed It Tuesday: Self-Driving Cars, Soy, Slumping Commodities Take Markets for a Ride
05:20PM  US Market Indexes Higher on Tuesday
05:04PM  Falling Revenue in Allergans US General Medicines Segment
04:17PM  Goldman Sachs, Pfizer Are Buys; J&J, Wendy's Downgraded
04:01PM  Boeing, UnitedHealth Dominate DJIA Tuesday
03:18PM  Pfizer Upgraded at Barclays at TheStreet
03:04PM  Allergans US Specialized Therapeutics Segment in 3Q16
02:18PM  Pfizer (PFE) Stock Rating Upgraded at Barclays
01:30PM  Does Procter & Gamble Co (PG) Represent a Good Addition to Your Portfolio? at Insider Monkey
12:50PM  Pfizer Inc. (PFE), Eli Lilly And Co (LLY) Impotence Drugs Price Increases Leave Patients Disgruntled at Insider Monkey
11:05AM  The Pfizer-Medivation Deal, Completed in 3Q16
11:00AM  Pfizer Shares up in Early Trading (PFE) at Investopedia
10:05AM  Pfizer Divests Hospiras Infusion System Business to ICU Medical
10:04AM  Elagolix May Become a Strong Growth Driver for AbbVie
09:52AM  Pfizer: Be Happy With the Dividend for Now
09:28AM  FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review CNW Group
09:09AM  Stock Futures Turn Mixed as U.S. Economy Grows, Oil Prices Slump
08:54AM  Morning Movers: Tiffany Jumps on Earnings; US Steel Sinks at
08:17AM  Early movers: TIF, UNH, MNK, PFE, AAPL, T, TIVO, C, ALL & more at CNBC
08:17AM  FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review PR Newswire
08:06AM  Pfizers Valuation Compared to Peers
08:06AM  German Merck, Pfizer get FDA priority review for cancer drug Reuters
06:25AM  Clifton on Trump trade: Financials good place to be
06:16AM  Stocks to Watch: November 29, 2016
Nov-28-16 04:19PM  Which companies will benefit from Cuban biotech?
01:11PM  5 Healthcare Stocks Hedge Funds Are Dumping Like Crazy at Insider Monkey
11:45AM  Pfizer Nixes 350-Job Expansion After Drug Fails (PFE) at Investopedia
10:05AM  Humira Has Been a Key Growth Driver for AbbVie in 2016
09:30AM  The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Priceline, Expedia and United Continental
07:57AM  J&J (JNJ) Confirms it Approached Actelion for Possible Deal
07:15AM  Short Sellers Hike Their Bets in Most Major Pharma Stocks
12:07AM  Tandem Drug-Price Increases Take Toll on Some Patients at The Wall Street Journal
12:07AM  Drugmakers Find Competition Doesnt Keep a Lid on Prices at The Wall Street Journal
Nov-27-16 04:54PM  Where Else Have We Seen Mallinckrodts Acquire to Invest Strategy?
07:05AM  [$$] Drugmakers Find Competition Doesn't Keep a Lid on Prices at The Wall Street Journal
07:00AM  [$$] Tandem Drug-Price Increases Take Toll on Some Patients at The Wall Street Journal
07:00AM  Drugmakers Find Competition Doesnt Keep a Lid on Prices
Nov-25-16 01:02PM  Top Research Reports for Black Friday 2016
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A.; and a research and development agreement with the National Cancer Institute to conduct clinical trials to evaluate investigational immunotherapy agents. The company has a partnership with The University of Pittsburgh to develop a computational model to identify the drivers of schizophrenia, Alzheimer's disease, and related brain diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MADDALUNA ANTHONY JExecutive Vice PresidentNov 09Sale33.0010,000330,000112,087Nov 10 07:44 PM
BOURLA ALBERTGroup PresidentNov 04Option Exercise24.9920,000499,800149,199Nov 07 05:58 PM
BOURLA ALBERTGroup PresidentNov 04Sale30.0518,390552,530130,809Nov 07 05:58 PM
HILL CHARLES HExecutive Vice PresidentNov 03Option Exercise21.0353,9181,133,896115,033Nov 07 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 02Option Exercise21.0332,545684,421122,087Nov 04 04:36 PM
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM
YOUNG JOHN DGroup PresidentMay 10Option Exercise25.8741,7001,078,779200,399May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Option Exercise24.43192,0004,690,560564,994May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Sale33.66192,0006,462,579372,994May 11 06:04 PM
YOUNG JOHN DGroup PresidentMay 10Sale33.5341,7001,398,277158,699May 11 06:04 PM
READ IAN CChairman & CEOMay 09Option Exercise25.74275,0007,078,2501,471,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Option Exercise22.2823,884532,136199,735May 11 04:35 PM
HILL CHARLES HExecutive Vice PresidentMay 09Sale33.8429,6001,001,65160,828May 11 04:35 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Sale33.7167,8842,288,669131,851May 11 04:35 PM
READ IAN CChairman & CEOMay 09Sale33.80275,0009,295,0391,196,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 05Option Exercise22.2856,0161,248,036231,867May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 05Sale33.7156,0161,888,144175,851May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Option Exercise22.2820,100447,828195,951May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Sale33.8720,100680,762175,851May 06 09:51 AM
DAMELIO FRANK AExecutive Vice PresidentMay 03Sale33.6587,0792,930,208372,994May 05 05:27 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541274,756Feb 26 03:05 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 24Option Exercise18.9062,4531,180,362140,772Feb 26 03:05 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9018,984358,79889,467Feb 26 03:05 PM
READ IAN CChairman & CEOFeb 24Option Exercise18.90584,11211,039,7172,030,151Feb 26 03:05 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541263,151Feb 26 03:05 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9052,570993,573188,679Feb 26 03:05 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9034,171645,832210,943Feb 26 03:05 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90210,2803,974,292622,467Feb 26 03:05 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90210,2803,974,292577,902Feb 26 03:05 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9078,8551,490,360149,135Feb 26 03:05 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9019,188362,65366,048Feb 26 03:05 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9034,171645,832149,482Feb 26 03:05 PM
BOURLA ALBERTGroup PresidentFeb 24Option Exercise18.9030,666579,587144,675Feb 26 03:03 PM
BOURLA ALBERTGroup PresidentDec 15Option Exercise26.2030,000786,000140,560Dec 16 06:46 PM
YOUNG JOHN DGroup PresidentDec 14Option Exercise26.2031,500825,300163,999Dec 16 06:55 PM